Cj Healthcare Corporation

Alteogen, Inc.

Penmix Ltd.

Ji Hyun Moon

Dong Eok Lee

Yoon Jung Lee

Won Jeong Lee

Chung Min Lee

Hoo Keun Oh

Sang Hyun Lee

Eun Young Choi

Soon Jae Park

Young Joon Park

Ki Wan Kim

Jee Won Ahn

Chi Hye Park

Hyoung Taek Lim

Sang Mee Lee

Hye Shin Chung

Gil Bu Kang

Dongkyu Park

Seung Jun Lee

Jung Min Yoo

Jung Rok Lee

Surin Kim

Young Sub Song

Joo Hwan Kim

Sung Yoo Cho

Hana Lee

Kyung Hwa Kim

Sang Yun Lee

Seung Ho Ji

Yoo Hee Yang

Se Jun Kim

Chang Bong Jun

Gyong Sik Ha

The present invention provides a composition for lipolysis, for example a pharmaceutical composition for preventing or treating obesity including localized fat deposits (LFD), comprising certain phosphocholine derivatives or pharmaceutically acceptable salt thereof. The pharmaceutical composition of the present invention shows an excellent lipolytic activity as well as a uniform lipolytic activity. And also, the pharmaceutical composition of the present invention can minimize side effects such as inflammation, tissue necrosis, etc., at the administered site. In addition, the pharmaceutical composition of the present invention has excellent storage stability.

Lipolytic composition containing phosphocholine derivatives

The present invention relates to a method for purifying darbepoetin alfa by selectively separating only a structural isoform having a high content of sialic acid from a mixture of structural isoforms of darbepoetin alfa having various contents of sialic acid. Since the method of the present invention is a novel method for purifying darbepoetin alfa which can be conveniently and simply produced, it is possible to remarkably increase productivity due to process efficiency improvement, as well as to yield high purity darbepoetin alfa when mass-producing darbepoetin alfa according to the present invention.

Method for purifying darbepoetin alfa

The present invention relates to a long-acting human growth hormone NexP-hGH protein and its production method. More specifically, it relates to a specific isoform of long-acting human growth hormone NexP-hGH protein in which human growth hormone is fused with a highly glycosylated alpha-1 antitrypsin mutant whereby long-acting properties in vivo are increased. The present invention also relates to a high-purity purification method for NexP-hGH, which includes the steps of: (a) carrying out anion-exchange resin chromatography on a biological emulsion comprising NexP-hGH in which human growth hormone is fused with an alpha-1 antitrypsin mutant; (b) carrying out hydrophobic resin chromatography on the biological emulsion comprising NexP-hGH, or on the eluate produced in step (a); and (c) carrying out affinity chromatography, entailing packing with a resin to which anti-alpha-1 antitrypsin antibody fragments are attached, on the biological emulsion comprising NexP-hGH and on the eluate produced in step (a) or step (b).

Method of purifying a long-acting human growth hormone

Growing community of inventors

Seoul, South Korea

Ji Hyun Moon